HALO:NASDAQ
Halozyme Therapeutics, Inc.
$68.55
arrow_downward
-0.03%(-0.020) 1D
$68.60
arrow_upward
+0.07% (+0.050)bedtimeAfter hours
Closed: Jun 18, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Open
$69.24
High
$69.24
Low
$67.02
Mkt. cap
8.13B
Avg. vol.
1.88M
Volume
3.65M
P/E ratio
24.66
52-wk high
$82.22
52-wk low
$51.06
EPS
$2.78
Beta
0.88
Shares outstanding
118.61M
No. of employees
423
Open
$69.24
High
$69.24
Low
$67.02
Mkt. cap
8.13B
Avg. vol.
1.88M
Volume
3.65M
P/E ratio
24.66
52-wk high
$82.22
52-wk low
$51.06
EPS
$2.78
Beta
0.88
Shares outstanding
118.61M
No. of employees
423
Analyst outlook
Analyst Ratings
Based on 6 analysts giving stock ratings to HALO in the past 3 months
Buy
Buy
3
Hold
2
Sell
1
12 month forecast
Based on 6 Wall Street analysts offering 12 month price targets for HALO in the last 3 months.
Highest
Current $68.55
$96.00 (+40.04%)
Average
$81.00 (+18.16%)
Lowest
$57.00 (-16.85%)
News stories
From sources across the web
Investing.com
·
3 days ago
H.C. Wainwright reiterates Halozyme stock rating on CMS rule impact
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com
AI content may include mistakes. Learn more